Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical progress, scientific data, and corporate developments in neurology and psychiatry. The company is advancing azetukalner, a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD), alongside early-stage Kv7 and NaV1.7 programs in pain and a NaV1.1 program in Dravet syndrome.
News related to XENE often covers clinical milestones, such as enrollment updates and anticipated topline data from Phase 3 studies like X-TOLE2 and X-TOLE3 in focal onset seizures (FOS), X-ACKT in primary generalized tonic-clonic seizures (PGTCS), and the X-NOVA and X-CEED programs in MDD and BPD. Xenon also issues press releases on long-term X-TOLE open-label extension (OLE) data, which include multi-year seizure frequency reductions and analyses of seizure freedom patterns with extended azetukalner treatment.
Investors and clinicians following XENE can expect scientific conference coverage from meetings such as the American Epilepsy Society Annual Meeting, where Xenon presents posters on epilepsy outcomes, depression burden in epilepsy, and pre-clinical data from its NaV1.1 Dravet syndrome program. Additional news items include corporate updates like quarterly financial results, investor conference presentations, investor webinars, and executive appointments, such as the appointment of a Chief Financial Officer in connection with anticipated commercialization activities.
Bookmark this page to monitor Xenon’s latest announcements on its Phase 3 epilepsy and mood disorder programs, early-stage pain pipeline, partnered work with Neurocrine Biosciences, and ongoing regulatory and investor communications.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its Q2 2022 financial and operational results after U.S. markets close on August 9, 2022. The conference call and webcast will be held at 4:30 PM Eastern Time the same day, providing updates on the company’s performance in developing therapeutics for neurological disorders, focusing on epilepsy. Investors can access the live webcast on Xenon's website, with a replay available afterward. The announcement underscores Xenon's commitment to addressing high unmet medical needs in neurology.
Xenon Pharmaceuticals (Nasdaq:XENE) will participate in the William Blair Biotech Focus Conference 2022 on July 12-13, 2022, in New York, NY. The company is focused on developing innovative therapeutics for neurological disorders, particularly in the area of epilepsy. A webcast of their fireside chat presentation will be available on their Investors section of the website. Xenon aims to address significant unmet medical needs through its clinical-stage product pipeline.
Xenon Pharmaceuticals has successfully closed its underwritten public offering of 9,098,362 common shares, raising approximately $287.5 million in gross proceeds. The offering included 1,229,508 shares from the underwriters’ option and 327,868 pre-funded warrants. Each common share was priced at $30.50, while pre-funded warrants were offered at $30.4999 with an exercise price of $0.0001. Major underwriters for this offering included Jefferies, J.P. Morgan, SVB Securities, and Stifel.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has priced its underwritten public offering of 7,868,854 common shares at $30.50 per share, alongside pre-funded warrants for 327,868 shares at $30.4999 each. The anticipated gross proceeds are approximately $250 million. An additional option allows underwriters to purchase up to 1,229,508 shares within 30 days. The offering is projected to close around June 27, 2022, subject to customary conditions. These transactions are part of an existing shelf registration statement with the SEC, filed on October 4, 2021.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced an underwritten public offering of its common shares and pre-funded warrants to purchase common shares. The offering is part of its existing shelf registration statement, and underwriters may purchase an additional 15% of shares at the public offering price within 30 days. The offering is subject to market conditions, and completion is uncertain.
Jefferies, J.P. Morgan, SVB Securities, and Stifel are the joint book-running managers for this offering.
Xenon Pharmaceuticals (Nasdaq:XENE) announced significant efficacy results from the Phase 2b X-TOLE trial of XEN1101, showing rapid reduction in focal onset seizures within one week across all doses. The median percent reduction was 55.4% for the 25 mg dose (p<0.001), with continued effectiveness in the open-label extension (OLE) phase, exceeding 70% reduction at 3 months and 80% at 12 months. The company plans to extend the OLE from three to five years. XEN1101 has shown a favorable safety profile, aligning with other anti-seizure medications.
Xenon Pharmaceuticals announced plans to initiate the Phase 3 clinical program for XEN1101 targeting focal onset seizures in the second half of 2022. Following a successful End-of-Phase 2 meeting with the FDA, Xenon expects to submit a New Drug Application (NDA) post-completion of the X-TOLE2 trial, built on strong Phase 2b data indicating significant seizure reduction. An additional Phase 3 trial, X-ACKT, for primary generalized tonic clonic seizures is also set to begin. Approximately 360 patients will partake in pivotal trials assessing the efficacy and safety of XEN1101.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a biopharmaceutical company specializing in neurology, will participate in one-on-one investor meetings and present at the 2022 Jefferies Healthcare Conference from June 8-10, 2022, in New York, NY. Ian Mortimer, President and CEO, will present on June 8 at 2:30 pm Eastern Time. A live webcast will be available on the company’s website, with archived recordings to follow. Xenon focuses on developing therapies for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) reported its financial results for Q1 2022, highlighting key developments in its clinical programs. The company is progressing towards an end-of-Phase 2 meeting with the FDA regarding XEN1101 for epilepsy, with Phase 3 initiation expected in H2 2022. Xenon has also initiated a Phase 2 trial for XEN1101 in major depressive disorder (MDD). Financially, the company recorded revenues of $8.8 million, up from $4.4 million YoY, but incurred a net loss of $19.7 million due to increased operational costs.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its first quarter 2022 financial results on May 10, 2022, after U.S. market close. The company, focused on developing therapeutics for neurological disorders, particularly epilepsy, will host a conference call at 4:30 PM ET to discuss the results. Participants can join using the provided dial-in numbers, with international access available. The event will also be streamed live on the company's investor website. Further information about their ongoing pipeline and developments can be found online.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
